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Abstract
As genomic sequencing expands into more areas of patient care, an increasing number of patients learn of the variants of
uncertain significance (VUSs) that they carry. Understanding the potential psychosocial consequences of the disclosure of a
VUS can help inform pre- and post-test counseling discussions. Medical uncertainty in general elicits a variety of responses from
patients, particularly in the growing field of medical genetics and genomics. It is important to consider patients’ responses to the
ambiguous nature of VUSs across different indications and situational contexts. Genetic counselors and other providers ordering
genetic testing should be prepared for the possibility of their patients’misinterpretation of such results. Pre-test counseling should
include a discussion of the possibility of VUSs and what it would mean for the patient’s care and its potential psychosocial
impacts. When a VUS is found, post-test counseling should include additional education and a discussion of the variant’s
implications and medical management recommendations based on the results. These discussions may help temper subjective
interpretations, unrealistic views, and decisional regret.
Keywords Variants of uncertain or unknown significance (VUS) . Affective response . Uncertainty . Genetic counseling .
Qualitative research
Introduction
As genomic sequencing expands into more areas of patient
care, an increasing number of patients learn of variants of
uncertain significance (VUSs) that they carry. Based on rec-
ommendations from the American College ofMedical Genetics
and Genomics, genetic variants can be classified into five dif-
ferent categories: pathogenic, likely pathogenic, variant of
uncertain significance, likely benign or benign (Richards et al.
2015). AVUS is a genetic change with unclear implications for
gene function. Multiple VUSs may be reported on any clinical
genomic test (Lazaridis et al. 2016). The relevance, if any, of the
VUS to a patient’s clinical history is not known due to a lack of
sufficient scientific evidence to determine the biological and
medical significance of the variant. It therefore cannot be un-
equivocally stated whether the variant is clinically causal, and
potentially actionable, or benign. Clinicians from a variety of
specialties will increasingly encounter genetic test results, but
many at this time lack the understanding and resources neces-
sary to discuss VUSs with patients (Macklin et al. 2018a).
For research purposes, VUSs can provide a wealth of oppor-
tunities for discovery, especially if the biological significance of
the gene itself is unknown. However, in a clinical context, they
can complicate matters. There remains no robust consensus on
how to handle VUSs in the clinical setting (Howard and
Iwarsson 2018; Han et al. 2017; Ackerman 2015). Any given
VUS could be pathogenic or completely benign. Additional
research is needed in order to guide reclassification of the var-
iant. Unless further instances of the same VUS are found, stud-
ied, and validated, reclassification is difficult to achieve with
any degree of confidence (Richards et al. 2015). ClinVar, for
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instance, is an online database that aggregates information on
variants from different laboratories in an effort to aid in
reclassifications and create agreement in variant classification.
For rare and novel variants, robust data for reclassification may
not be feasible for a significant amount of time without costly
functional analysis or until more individuals are sequenced and
phenotypic and genotypic information is shared on platforms
such as ClinVar (Landrum et al. 2017; Rehm et al. 2015).
Some experts have argued that a VUS should be ignored
during clinical decision making stating that it is inappropriate
to report patients’ VUSs due to the uncertainty regarding clin-
ical significance (Berg et al. 2013). Disclosure to a patient could
possibly suggest some latent significance, even if clinicians
explicitly qualify them as uncertain. Over-estimation of the
clinical significance could be misleading or stand as a distrac-
tion, and resources could be wasted on analyses that do not
have any medical relevance (Resta 2014; Berg et al. 2013).
Others have called for more detailed and widely accepted
guidelines for the assessment of VUSs (Dewey et al. 2014).
Until that time, when a VUS is discovered, the ethical and
psychosocial implications of returning these variants must be
debated, assessing the situation subjectively and more or less
ad hoc.
Medical uncertainty in general elicits a variety of responses
from patients (Mishel 1988), particularly in the growing field
of medical genetics and genomics (Pyeritz 2017; Newson
et al. 2016; Han et al. 2017; Howard and Iwarsson 2018;
Biesecker et al. 2014). Understanding the psychosocial con-
sequences of disclosing a VUS can inform pre- and post-test
counseling discussions. To this end, this review article ex-
plores the spectrum of responses from patients regarding in-
conclusive test results across different indications.
The literature described here includes articles with qualita-
tive (interviews and free-text response) and quantitative (ques-
tionnaire response) data exploring the range of reactions that
patients have when receiving a VUS result from genetic test-
ing. Several factors seem to influence patients’ responses, in-
cluding the clinical indication, their personal health, progno-
sis, and level of clinical suspicion regarding the VUS. Some
examples of the positive reactions described were hope for
future VUS reclassification, beneficence derived from partic-
ipating in research, relief, empowerment, and validation.
Positive reactions sometimes occurred from misinterpretation
of the result, i.e. over-interpretation of a VUS. Poor compre-
hension also led to some negative reactions. Negative feelings
described included sadness, disappointment, isolation, hope-
lessness, frustration regarding the uncertainty, and regret (see
Tables 1 and 2).
Positive affective response
When receiving a VUS result or when presented with a hypo-
thetical VUS, many participants (specifically tumor profiling
oncology, cardiomyopathy, and undiagnosed disease genetic
testing patients), expressed the positive feeling of beneficence
stemming from furthering scientific understanding by contrib-
uting to research (undiagnosed disease: Skinner et al. 2017;
Werner-Lin et al. 2018. Cardiomyopathy: Lawal et al. 2018;
Burns et al. 2017. Tumor profiling: Marron et al. 2016;
Makhnoon et al. 2019) (Table 2).
Some patients expressed positive attitudes toward their re-
sult if they believed that the VUS would be reclassified or
could potentially lead to an answer in the future (hereditary
breast cancer: Kaphingst et al. 2016; undiagnosed diseases:
Skinner et al. 2017; VUS patients seeking to be in reclassifi-
cation research: Makhnoon et al. 2018; chromosome array
prenatal setting: Jez et al. 2015). In cases of rare or undiag-
nosed diseases, some participants viewed a VUS positively
because they interpreted it as causal or likely pathogenic (pre-
natal: Kiedrowski et al. 2016; undiagnosed disease: Skinner
et al. 2017). This view sometimes led participants to feel
empowered and validated (prenatal: Kiedrowski et al. 2016;
undiagnosed disease: Skinner et al. 2017; Werner-Lin et al.
2018). Furthermore in the prenatal setting, some participants
felt that the result would help them access more therapeutic
amenities and assistance from the government, school sys-
tems, and providers (Reiff et al. 2012; Kiedrowski et al.
2016; Wilkins et al. 2016; Turbitt et al. 2015).
Other patients viewed VUSs optimistically, because they
accurately interpreted their results as specifically indefinite,
thus as a better outcome than had a pathogenic test variant
been found (Lynch syndrome: Solomon et al. 2017; breast
cancer: O'Neill et al. 2009; reclassification research partici-
pants: Makhnoon et al. 2018). However, some participants
with a VUS result chose to pursue increased cancer screenings
or enhanced medical monitoring despite the admitted ambigu-
ity of the result (Lynch syndrome: Solomon et al. 2017; breast
cancer: Lumish et al. 2017; undiagnosed disease: Werner-Lin
et al. 2018).
Many of the research participants who were presented with
the hypothetical option of receiving a VUS wanted to receive
such results because they saw some value in the information
(breast cancer: Kaphingst et al. 2016; tumor: Marron et al.
2016; Yushak et al. 2016; research: Jamal et al. 2017;
Biesecker et al. 2014).
Negative affective response
One of the most reported negative effects of a VUS result
on patients is stress and distress, particularly for breast
cancer, tumor profiling, and cardiomyopathy patients
(breast cancer: Kaphingst et al. 2016; O'Neill et al.
2009; Lumish et al. 2017. Bradbury et al. 2012; tumor:
Makhnoon et al. 2019; cardiomyopathy: Wynn et al.
2018a. reclassification research: Makhnoon et al. 2018.).
One article found that the distress score measured in the
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paper was approximately the same (higher than those who
received a negative result) for VUS recipients as for those
parents of patients who received a pathogenic result from
diagnostic exome sequencing (undiagnosed disease:
Wynn et al. 2018b). However, a more recent article about
breast cancer patients showed that worry levels among
patients who received a VUS was more similar to those
who received a negative result (less worry than those who
received a pathogenic result) (Katz et al. 2018). Another
study found that while distress decreased from before test-
ing to 1 month after disclosure for participants who re-
ceived a definitively negative result, participants with a
VUS result reported stable distress from before testing
through 6 months after disclosure, only decreasing at
12 months (breast cancer: O'Neill et al. 2009). Distress
is not only a concern for patients who receive a VUS
result from testing, but also for those who receive such
a result about their offspring (breast cancer: Bradbury
et al. 2012).
Symptoms and affected status contributed to negative
attitudes regarding the disclosure of a VUS. Those without
symptoms and those who had been told their VUS would
likely turn out to be benign expressed regret or had lower
satisfaction with testing than those with symptoms and
those who had been told their VUS would more likely
end up being reclassified as pathogenic (cardiomyopathy:
Table 1 The optimistic and negative attitudes from the literature are extracted and organized by indication in Table 1. (Studies where the participants
were asked about what they thought about VUSs, but they did not have a VUS result, are defined as “hypothetical”)
Indication Positive affective response to VUS themes Negative affective response to VUS
themes
Undiagnosed disease
3 articles, Combined N = 77
• Potential answers in the future
• Optimism
• Contributing to research
• Empowerment
• Gratitude
• Disappointment at not receiving a
diagnosis
• Distress over uncertainty
• Frustration
• Disappointment
Prenatal /chromosome array parents
4 articles,
Combined N = 64
1 hypothetical article, N = 147
• Relief
• Comfort
• Happiness
• Validation
• Acceptance
• Extra information
• Preparedness
• Hopelessness
• Guilt
• Isolation
• Feeling of permanence
• Distress from uncertainty
• Lack of answers
Cardiomyopathy
3 articles
Combined, N = 93
• Contributing to research
• Contributing to future knowledge
• Useful information
• Sense of self awareness
• Dissatisfaction from uncertainty
• Decisional regret of learning about
their result
• Lack of understanding and recall
Fabry-associated c.427G >A (p.A143T)
variant in GLA
1 article, N = 27
• Ability to plan for the future
• Inform clinical care
• Frustrated by lack of clear
information
• Decisional regret of learning about
their result
Lynch syndrome
1 article, N = 27
1 hypothetical article, N = 19
• Relief
• Empowerment
• Hope
• Viewed not as definitive diagnosis, therefore better than a
positive test result
• Sadness
• Conflict
• Disappointment
• Shocking
• Decisional regret
Breast cancer
(of the articles reviewed)
5 articles combined
N = 246
1 hypothetical article, N = 60
• Viewed not as definitive, therefore better than a positive test
result
• Potential answers in the future
• Frustration about uncertainty
• Isolation
• Disappointment
• Distress
• Greater sustained distress
Tumor
1 article n = 11
2 Combined hypothetical, N = 458
• Participation in research
• Hope for the future
• Distress
• Uncertainty
• Worry about increased medical costs
• Confusion
Research participants
1 article, N = 26
2 hypothetical articles combined, N = 241
• Optimism that it would be reclassified
• Opportunity
• Furthering scientific knowledge
• Uncertainty
• Pessimism
• Fear
• Distrust
• Misunderstanding
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Table 2 Affective responses to variants of uncertain or unknown significance results broken down by article and organized by indication
Disease Study Regret Distress/
anxiety
Poor
comprehension/
recall
Altruism Potential
answers
Other
Cardiomyopathy Lawal et al. 2018
VUS, n = 79
x x Overall sense of health awareness
Burns et al. 2017
VUS, n = 9 patients
x x
Wynn et al., 2018a
VUS, n = 5 patients
x x
Fabry Macklin et al. 2018
VUS, n = 27 patients
x x Interest in it being reclassified
Lynch syndrome Solomon et al. 2017
VUS, N = 27 patients
x x Better than being positive, empowered to take
precautions, increased cancer screening, hope for
reclassification
Hitch et al. 2014
N = 19 hypothetical
Better than being diagnosed with cancer, interest in it
being reclassified
Tumors or other
cancers
Yushak et al. 2016
N = 413 hypothetical
x Concern over increased medical costs and additional
testing
Marron et al. 2016
N = 45 hypothetical
x
Makhnoon et al. 2019
VUS n = 11
x x x Confusion
Breast cancer Richter et al. 2013
VUS, n = 36 patients
x decreased perceived risk; intermediate level of worry
Kaphingst et al. 2016
N = 40 hypothetical
x x Would not want to know about it until it is reclassified
Lumish et al. 2017
VUS, n = 34
x x x Increased cancer screening
O’Neill et al. 2009
VUS, n = 19 patients
x Better than receiving a pathogenic result
Katz et al. 2018, VUS
n = 134
x Low worry, higher in less educated, younger, and
minorities
Bradbury VUS,
n = 23 parents of 43
children
x Neutral, useful
Prenatal Kiedrowski et al.
(2016)
VUS n = 14
x x Over-interpretation (view VUS as pathogenic); access
more therapeutic amenities and assistance
Jez et al. 2015 VUS,
n = 30
x Access more therapeutic amenities and assistance
Wilkins et al. 2016
VUS, n = 9
Access more therapeutic amenities and assistance
Turbitt et al. 2015
n = 147 hypothetical
Access more therapeutic amenities and assistance
Reiff et al. 2012
VUS, N = 11
x x Access more therapeutic amenities and assistance
Undiagnosed
disease
Skinner et al.
VUS, n = 32
x x Over-interpretation (view VUS as pathogenic),
empowered and validated
Werner-Lin et al.
2018
VUS, n = 10 patients
x x x Frustration, disappointed, minimalized, normalized,
more informed, empowerment, gratitude
Wynn et al. 2018b x x Frustration; affect non-medical care
Research Biesecker et al. 2014
Hypothetical, N = 39
x x x Normalized, expected, information, a loss
Jamal et al. 2017
Hypothetical, n = 202
Increased screening, no value, surprise, neutral
Makhnoon et al. 2018
VUS, n = 26
x x Better than pathogenic
142 J Community Genet (2020) 11:139–145
Wynn et al. 2018a; Lawal et al. 2018. Fabry: Macklin et al.
2018b; Lynch syndrome: Solomon et al. 2017; breast can-
cer: Lumish et al. 2017).
A negative outcome of receiving a VUS is that participants
had a greater lack of understanding and recall regarding a
VUS than those who had received a definitive test result (car-
diomyopathy: Burns et al., Richter et al. 2013; breast cancer:
Lumish et al. 2017; Makhnoon et al. 2018; Kaphingst et al.
2016; Reiff et al. 2012; undiagnosed disease: Wynn et al.
2018b).
Other negative sentiments expressed in the literature in-
cluded shock, guilt, isolation, frustration and hopelessness
and worry about increased medical costs.
Discussion
Despite some variability of specific responses, several themes
repeated across indications between the different types of clin-
ical scenarios and the way patients or families viewed the
VUS result. Some patients viewedVUSs optimistically, others
negatively, and sometime expressed a nuanced combination of
both. This heterogeneity of positive and negative attitudes
does not seem to correlate with the type of indication but
rather with the patient’s own interpretation of the result within
the context of their life.
The literature has shown that patients often misinterpret
VUSs (Grover et al. 2009; Lumish et al. 2017; Richter et al.
2013; Makhnoon et al. 2018). This misunderstanding contrib-
utes to patients’ overall attitudes (either positive or negative)
toward the result and how they act upon it. The difficulty in
successfully communicating the clinical uncertainty character-
istic of a VUS is not limited to any particular indication.
In some scenarios, patients assigned meaning and greater
classificational specificity to their VUS on a likely pathogenic
to likely benign scale. Sometimes, breast cancer patients
viewed VUSs as more similar to a negative result than to a
positive result (Richter et al. 2013). Conversely, undiagnosed
patients were more likely to view a VUS as pathogenic, be-
cause they perceived it as a potential answer for their health
history (Skinner et al. 2017). Parents were more likely to pres-
ent optimistic views of their child’s uncertain chromosome
microarray results if the parent considered it to be causal or
likely pathogenic (Kiedrowski et al. 2016). The subjective
nature of VUS interpretation is important to consider upon
disclosure. Over-interpretation of a VUS has the potential to
lead to harm through unwarranted surveillance or inappropri-
ate treatment. Furthermore, if a family member tests negative
for a familial VUS, they may wrongly interpret that to mean
they have no increased risk for the associated condition.
Patients’ interest in reclassification was also shown to be
contextual. In the Fabry-associated case, the severity of pa-
tient’s reported symptoms correlated with the value they saw
in the variant being confirmed as pathogenic (Macklin et al.
2018b). In an article about cardiomyopathy-associated VUSs,
patients were informed whether their result was more likely
benign or more likely pathogenic. Patients who were told that
the VUS was more likely pathogenic perceived more value in
the disclosure of a VUS. On the other hand, patients who
received a result that was described as more likely benign
saw less value in the disclosure of the VUS (Lawal et al.
2018).
In cases of undiagnosed disease, VUSs are often seen by
the patient as a potential indication of future diagnosis that
could help them get access to care and social and clinical
validation (Skinner et al. 2017; Makhnoon et al. 208). This
finding is important, because uncertainty about a diagnosis in
general has been found to correlate with negative attitudes
(Madeo et al. 2012). However, for undiagnosed diseases, an
uncertain result is seen as a partial answer and therefore leads
to optimistic views (Kiedrowski et al. 2016; Skinner et al.
2017). Patients’ responses to uncertainty, therefore, are not
simply a function of the uncertainty itself but of that uncer-
tainty within the specific context of their own diagnostic od-
yssey. The return of variants of uncertain significance cannot
merely be valued in the abstract. The likelihood of mis- and
over-interpretation varies based on the diverse psychosocial
needs for evidence to legitimize particular patients’ suffering
within their own clinical course.
Decisional regret is often mentioned in the literature. In one
paper related to Lynch syndrome, the only people with VUSs
that expressed regret regarding testing were unaffected pa-
tients (Solomon et al. 2017). Patients who received a cardio-
myopathy VUS that was described as more likely benign in-
dicated more decisional regret (Lawal et al. 2018). From these
studies, it appears that if a VUS result is less likely to inform
health care decisions, patients may express more regret in
learning the inconclusive result. Further studies of people
who communicate regret after receiving a VUS need to be
conducted in order better to understand what prompts this
feeling. By learning more about these patients, we may even-
tually be able to predict and help prevent such regret.
Conclusion
Genetic counselors and other providers ordering genetic test-
ing should be prepared for the possibility of their patients’
expressing regret or therapeutic misconception (Appelbaum
and Lidz 2008). Pre-test counseling should include a discus-
sion of the possibility of VUS and what it would mean for the
patient’s care (Daly et al. 2001). When a VUS is found, post-
test counseling should include a discussion of the variant’s
implications and what patients should and should not do with
the results. The discussion should facilitate patient consider-
ation of this result in the long term (Johnson et al. 2016).
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Development of shared decision-making tools may facilitate
patient–clinician conversation and support better understand-
ing of the results, and subsequently a better response to po-
tential long-term psychosocial consequences, allowing ulti-
mately for a truly informed decision-making process
(Hargraves et al. 2016).
Genetic counselors could also provide patients with educa-
tional information that can be shared with other providers who
may not be as familiar with genetics. Furthermore, genetic
counselors could send an annotated note to other providers
to explain in general what a VUS is, but also what it might
mean specifically in the patient’s context considering the pa-
tient’s medical and familial history. Laboratories and genetic
counselors could also offer resources for patients to become
involved in reclassification research or variant registries, such
as the PROMPT Registry. They should also provide specific
details for how they will recontact the patient if the variant
gets reclassified as pathogenic or benign but also recommend
that the patient follow-up every few years as well. These re-
sources and discussions emphasizing uncertainty may help
temper subjective interpretations, unrealistic views, and deci-
sional regret.
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